IOVA logo

IOVAIovance Biotherapeutics Inc

$4.02
$0.0594
(1.50%)
Pre-Market
Updated: 07:04 AM EDT·Prev Close $3.96
EarningsAug 6
Mkt Cap$1.69B
Vol2,736.00
News
all
press releases
Iovance Biotherapeutics, Inc. (IOVA) a Top Penny Stock to Buy on Amtagvi Strong Adoption
Iovance Biotherapeutics, Inc. (IOVA) a Top Penny Stock to Buy on Amtagvi Strong Adoption...
Yahoo! Finance: News
News Placeholder
More News
News Placeholder
IBRX Stock Outlook After Q1 Results and a New FDA Review
ImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.
Zacks
News Placeholder
ImmunityBio: Anktiva Explained and What Comes Next
IBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.
Zacks
News Placeholder
AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?
Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.
Zacks
News Placeholder
IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%
Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.
Zacks
News Placeholder
Why Is IOVA Stock Falling Today?
During the first quarter, Iovance posted a 45% increase in revenue to $71.4 million, which came in below Wall Street’s estimates of $75.6 million, according to Fiscal.ai data.
Stocktwits
News Placeholder
Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates
Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 0.00% and -7.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Alvotech (ALVO) Reports Q1 Loss, Lags Revenue Estimates
Alvotech (ALVO) delivered earnings and revenue surprises of -28.57% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of -18.96% and -15.66%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 6.3% - Still a Buy?
Iovance Biotherapeutics (NASDAQ:IOVA) Trading 6.3% Higher - Here's What Happened...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.